

*This is an English translation of the Swedish original. In case of discrepancies, the Swedish original shall prevail.*

Press release | Umeå December 2, 2021

## Lipigon announces positive results from preclinical study for lipid-lowering drug candidate Lipisense

**Lipigon Pharmaceuticals AB ("Lipigon"), which is developing therapeutics for lipid-related diseases, today announced the completion of another safety study for the drug candidate Lipisense has been completed with positive results. The 28-day toxicology study showed that all dose levels were well tolerated.**

Lipisense is a drug candidate for the treatment of diseases with abnormal levels of lipids in the blood, primarily triglycerides, and a first-in-class treatment with a unique mechanism of action. Elevated triglycerides are a risk factor present in several diseases and Lipisense has the potential to normalize triglyceride levels. The large population of patients with elevated triglycerides is heterogeneous—comprising patients with rare genetic disorders to large patient groups, such as type 2 diabetics.

The reported study is one of several preclinical studies that will form the basis for a clinical trial application, expected to be submitted in the first quarter of 2022.

### **CEO Stefan K. Nilsson comments:**

"I am pleased to note that the results, as expected, do not show any safety issues and that we will continue according to plan with the start of the phase I study during the second quarter of 2022, which we have previously communicated."

### **About Lipisense**


The drug candidate is an RNA therapeutics that prevents the cells from producing the disease-promoting target protein ANGPTL4 by destroying the protein-coding RNA before the target protein has been formed. The target gene has a strong genetic association to plasma lipid levels and related diseases, such as type 2 diabetes and cardiovascular disease.

### **For more information, please contact:**

Stefan K. Nilsson, CEO, Lipigon

Email: [stefan@lipigon.se](mailto:stefan@lipigon.se)

Phone: +46 705 78 17 68



Tvistevägen 48 C, SE-90736 Umeå, Sweden

Tel: +46(0)705781768, [info@lipigon.se](mailto:info@lipigon.se)

Org.nr: 556810-9077

[lipigon.se](http://lipigon.se)




*This is information that Lipigon Pharmaceuticals AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 09:25 am CET, on 2 December 2021.*

### **About Lipigon**

Lipigon develops novel therapeutics for patients with lipid metabolism disorders. The company is based on over 50 years of lipid research at Umeå University, Sweden. Lipigon's initial focus is on orphan drugs and niche indications, but in the long term, the company will have the opportunity to target broader indications in the area, such as diabetes and cardiovascular disease. Lipigon's pipeline includes four active projects: the RNA-drug Lipisense, for treatment of hypertriglyceridemia; an RNA-drug for treatment of acute respiratory distress syndrome; a gene therapy treatment for the rare disease lipodystrophy, together with Combigene AB (publ); and a small molecule program for treatment of dyslipidemia in collaboration with HitGen (Inc).

The company's share (LPGO) is traded on the Nasdaq First North Growth Market. Certified Adviser is G&W Fondkommission, email: [ca@gwkapital.se](mailto:ca@gwkapital.se), phone: +46 8 503 000 50.



Tvistevägen 48 C, SE-90736 Umeå, Sweden  
Tel: +46(0)705781768, [info@lipigon.se](mailto:info@lipigon.se)  
Org.nr: 556810-9077  
**lipigon.se**